Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWH NASDAQ:CLYM NASDAQ:MOLN OTC:ZOMDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.84+7.7%$0.47$0.26▼$1.02$171.73M1.04164,158 shs1.05 million shsCLYMClimb Bio$2.23-3.0%$1.61$1.05▼$8.79$155.86M-0.11878,948 shs288,883 shsMOLNMolecular Partners$3.83+6.3%$3.70$3.36▼$7.60$145.36M1.14,219 shs4,139 shsZOMDFZomedica$0.04+6.3%$0.04$0.02▼$0.16$40.28M1.63.86 million shs2.11 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness+7.69%+18.11%+79.68%+162.42%-9.58%CLYMClimb Bio-3.04%-6.30%+46.71%+84.30%+222,999,900.00%MOLNMolecular Partners+3.24%+1.73%+1.49%-2.02%-39.57%ZOMDFZomedica+6.33%+4.30%+18.11%-8.96%-70.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAWHAscend Wellness0.8982 of 5 stars0.05.00.00.00.61.70.6CLYMClimb Bio3.3276 of 5 stars3.70.00.00.03.32.51.3MOLNMolecular Partners1.7118 of 5 stars3.82.00.00.02.40.00.0ZOMDFZomedica0.6075 of 5 stars0.05.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 1.00SellN/AN/ACLYMClimb Bio 3.33Buy$9.00303.59% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00213.73% UpsideZOMDFZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZOMDF, AAWH, CLYM, and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025CLYMClimb BioBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/15/2025CLYMClimb BioRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$9.008/12/2025AAWHAscend WellnessZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/6/2025CLYMClimb BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.33$0.13 per share6.64$0.69 per share1.22CLYMClimb BioN/AN/AN/AN/A$2.74 per shareN/AMOLNMolecular Partners$681K226.78N/AN/A$3.20 per share1.20ZOMDFZomedicaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.42N/AN/AN/A-15.47%-72.18%-9.55%N/ACLYMClimb Bio-$73.90M-$0.70N/AN/AN/AN/A-23.10%-22.47%11/11/2025 (Estimated)MOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)ZOMDFZomedicaN/A-$0.10N/A∞N/AN/AN/AN/AN/ALatest ZOMDF, AAWH, CLYM, and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/12/2025Q2 2025CLYMClimb Bio-$0.19-$0.13+$0.06-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AZOMDFZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80CLYMClimb BioN/A14.0814.08MOLNMolecular PartnersN/A9.3515.28ZOMDFZomedicaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.31%CLYMClimb Bio69.76%MOLNMolecular Partners26.55%ZOMDFZomedica8.95%Insider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.38%CLYMClimb Bio0.80%MOLNMolecular Partners5.93%ZOMDFZomedica5.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.44 million166.44 millionNot OptionableCLYMClimb Bio967.76 million67.22 millionN/AMOLNMolecular Partners18040.38 million37.98 millionNot OptionableZOMDFZomedica50979.95 millionN/AN/AZOMDF, AAWH, CLYM, and MOLN HeadlinesRecent News About These CompaniesZomedica Corporation and VerticalVet partner to deliver advanced veterinary technologies to independent practicesAugust 22, 2025 | pharmabiz.comPZomedica Corp. Reports Q2 2025 Financial ResultsAugust 22, 2025 | msn.comZomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent PracticesAugust 19, 2025 | accessnewswire.comAZomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL(R) Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary MedicineAugust 12, 2025 | accessnewswire.comAZomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support GrowthAugust 6, 2025 | accessnewswire.comAZomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | financialpost.comFZomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | globenewswire.comZomedica's Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for PetsJuly 16, 2025 | accessnewswire.comAZomedica Announces Strategic PulseVet(R) Shock Wave Partnership with World Equestrian Center – OcalaJuly 10, 2025 | accessnewswire.comAZomedica Announces Issuance of Additional Patent for its TRUVIEW(R) MicroscopeJune 24, 2025 | accessnewswire.comAZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | finanznachrichten.deZomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform(R) - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | accessnewswire.comAZomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample DilutionMay 21, 2025 | accessnewswire.comAZomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 19, 2025 | accessnewswire.comAZomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic ChallengesMay 16, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comZomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support GrowthMay 15, 2025 | accessnewswire.comAZomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave TherapyMay 13, 2025 | accessnewswire.comAZomedica to Report First Quarter 2025 Financial Results with a Business Update on Thursday, May 15, 2025 at 4:30 pm ETMay 9, 2025 | accessnewswire.comAZomedica CFO Scott Jordan Resigns, Interim Replacement NamedApril 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZOMDF, AAWH, CLYM, and MOLN Company DescriptionsAscend Wellness OTC:AAWH$0.84 +0.06 (+7.69%) As of 08/29/2025 03:59 PM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.Climb Bio NASDAQ:CLYM$2.23 -0.07 (-3.04%) As of 08/29/2025 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Molecular Partners NASDAQ:MOLN$3.82 +0.23 (+6.25%) Closing price 08/29/2025 02:17 PM EasternExtended Trading$3.78 -0.05 (-1.31%) As of 08/29/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Zomedica OTC:ZOMDF$0.04 +0.00 (+6.33%) As of 08/29/2025 03:59 PM EasternZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
